Floatz logo

FFNP

Breast Lobular Carcinoma

University of Wisconsin, MadisonSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

0 Active assets in the Breast Lobular Carcinoma cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Royal Marsden NHS Foundation Trust
Phase 2B
Crizotinib
Royal Marsden NHS Foundation Trust
Phase 2B
Naltrexone
Dana-Farber Cancer Institute
Phase 2CCC
AE-BROCCOLI
Roswell Park Cancer Institute
Early Phase 1CC

Same molecule, other indications

FFNP is also rated in:

invasive breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
Her2-receptor negative breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →